ATRA · Atara Biotherapeutics, Inc.
$9.25
-0.19 (-2.01%)
At close · Sep 3
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$94.76M
Shares
10.04M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$120.77M
-6.3%
FY2025
Net Income
$32.69M
+138.3%
FY2025
Operating Margin
29.69%
+94.4pp
FY2025
Diluted EPS
$2.57
+122.5%
FY2025
Operating Cash Flow
-$50.94M
+25.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.19M | $120.77M | $128.94M | $8.57M | $63.57M | — | — | — | — | — | — | — | — | — | |
| $4.21M | $37.45M | $151.48M | $224.79M | $272.53M | $282M | $244.65M | $216.1M | $167.46M | $81.21M | $56.51M | $41.62M | $15.45M | $4.31M | |
| $15.68M | $26.25M | $39.89M | $50.91M | $71.55M | $78.8M | $64.4M | $79.58M | $69.65M | $40.33M | $24.73M | $16.83M | $12.71M | $3.76M | |
| $128K | $2.12M | $5.05M | $4.83M | $5.65M | $9.35M | $8.33M | $7.07M | $3.73M | $956K | $383K | $48K | — | — | |
| $2.04M | $12.61M | $5.11M | $6.73M | $5.96M | — | — | — | — | — | — | — | — | — | |
| $313.46M | — | — | — | $344.09M | $360.8M | $309.05M | $295.68M | $237.11M | $121.53M | $81.24M | $58.45M | $28.16M | $8.62M | |
| $20.42M | $84.91M | $212.38M | $284.58M | $344.09M | — | — | — | — | — | — | — | — | — | |
| -$14.23M | $35.86M | -$83.44M | -$276.01M | -$280.51M | -$340.46M | -$309.05M | -$295.68M | -$237.11M | -$121.53M | -$81.24M | -$58.45M | -$28.16M | -$8.62M | |
| — | 29.69% | -64.71% | -3219.48% | -441.25% | — | — | — | — | — | — | — | — | — | |
| -$14.1M | $37.98M | -$78.39M | -$271.18M | -$274.86M | -$331.12M | -$300.72M | -$288.61M | -$233.38M | -$120.58M | -$80.86M | -$58.4M | — | — | |
| $2.82M | $3.79M | $4.62M | $5.29M | $373K | — | — | — | — | — | — | — | — | — | |
| $436K | $683K | $2.11M | $5.43M | $3.06M | — | — | — | — | — | — | — | — | — | |
| -$45K | -$34K | $528K | -$246K | -$700K | $367K | $2.45M | $4.72M | $6.37M | $2.03M | $2.2M | $1.22M | $125K | $12K | |
| — | — | — | $0 | $50.24M | $0 | $0 | — | — | — | — | — | — | — | |
| -$16.66M | $32.72M | -$85.42M | -$276.11M | -$228.29M | -$340.1M | -$306.61M | -$290.96M | -$230.74M | -$119.51M | -$79.04M | -$57.23M | -$28.03M | -$8.6M | |
| $29K | $31K | -$12K | $15K | $12K | $46K | $15K | $12K | -$44K | -$14K | $10K | -$9000 | -$25K | $170K | |
| -$16.69M | $32.69M | -$85.4M | -$276.13M | -$228.3M | -$340.14M | -$306.62M | -$290.98M | -$230.7M | -$119.49M | -$79.05M | -$57.22M | -$28.01M | -$8.77M | |
| — | 27.07% | -66.23% | -3220.88% | -359.12% | — | — | — | — | — | — | — | — | — | |
| -$16.69M | $32.68M | -$85.19M | -$274.26M | -$230M | -$340.81M | -$306.54M | -$290.42M | -$230.89M | -$119.46M | -$78.71M | -$57.64M | -$28.11M | -$8.77M | |
| USD/shares | -$1.73 | $2.61 | -$11.41 | -$65.19 | -$56.00 | -$90.75 | -$103.75 | — | — | — | — | — | — | — |
| USD/shares | -$1.73 | $2.57 | -$11.41 | -$65.19 | -$56.00 | -$90.75 | -$103.75 | — | — | — | — | — | — | — |
| shares | — | 12.54M | 7.49M | 4.24M | 4.08M | 3.75M | 2.96M | 2.05M | 1.75M | 1.19M | 1.15M | 1.02M | 199.44K | 38.63K |
| shares | — | 12.72M | 7.49M | 4.24M | 4.08M | 3.75M | 2.96M | 2.05M | 1.75M | 1.19M | 1.15M | 1.02M | 199.44K | 38.63K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 63 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.84×
EV/EBIT
—
Peer median 11.63×
P/E (TTM)
—
Peer median 9.75×
Peer medians compare against the 288 similar-size Biotechnology companies (of 514 listed).
Key facts
CIK
1604464
CUSIP
046513206
13F (30d)
33 filings
32 filers
Visit website
Investor relations